Announcement PDF RNS Number : 7812O Thalia Therapeutics PLC 31 July 2026 31 July 2026 Thalia Therapeutics plc ("Thalia" or the "Company") Total Voting Rights Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces, for the purposes of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 1,775,720,897 ordinary shares of 0.4 pence each with voting rights. The above figure may be used by shareholders as the denominator in calculations to determine whether they are required to notify their interest in, or a change in their interest in, the share capital of the Company. - Ends - For more information please contact: Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer Via Thalia Investor Hub https://investors.thaliatx.com/link/PGRqxr SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Tel: +44 (0)20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/Guy McDougall Tel: +44 (0)20 3657 0050 Northstar Communications Limited Investor relations and Communications Sarah Hollins Cohesion Bureau Investor relations and Communications Mary-Ann Chang Tel: +44 (0)20 7183 2463 Tel: +44 (0)7483 284853 About Thalia Therapeutics plc Thalia Therapeutics is a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease. With a growing, differentiated pipeline, de- risked by validated therapeutic targets, we aim to treat disease at its source by silencing or modifying the genes that cause or contribute to it. Our clinical-stage programme miRisten is a microRNA therapeutic in development for Acute Myeloid Leukaemia (AML). Alongside this, our preclinical bispecific siRNA programme is being developed as a potentially long-acting treatment for atherosclerotic cardiovascular disease by addressing two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics. For further information visit www.thaliatx.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END TVRWPUAUMUPQGUG